NeuroBo Pharmaceuticals, Inc. announced that DA-1726, a novel oxyntomodulin analogue functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, had been shown to elicit superior weight loss efficacy compared to Semaglutide (SEMA) and Tirzepatide (TIR) in preclinical testing. This, and other data, was presented in one ePoster theater discussion and two general poster presentations at the American Diabetes Association's 83rd Scientific Sessions, held June 23-26, 2023.